SIOX Sio Gene Therapies Inc

Price (delayed)

$2.02

Market cap

$140.51M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.62

Enterprise value

$22.77M

Highlights
The equity has surged by 100% year-on-year and by 39% since the previous quarter
The debt has dropped by 92% year-on-year

Key stats

What are the main financial stats of SIOX
Market
Shares outstanding
69.56M
Market cap
$140.51M
Enterprise value
$22.77M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.96
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$31.84M
EBITDA
-$29.37M
Free cash flow
-$46.99M
Per share
EPS
-$0.62
Free cash flow per share
-$0.9
Book value per share
$2.1
Revenue per share
$0
TBVPS
$2.59
Balance sheet
Total assets
$135.15M
Total liabilities
$11.78M
Debt
$1.24M
Equity
$123.37M
Working capital
$121.49M
Liquidity
Debt to equity
0.01
Current ratio
12.2
Quick ratio
10.97
Net debt/EBITDA
4.01
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-33.7%
Return on equity
-38.1%
Return on invested capital
-469.4%
Return on capital employed
-25.6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SIOX stock price

How has the Sio Gene Therapies stock price performed over time
Intraday
-0.49%
1 week
-4.27%
1 month
-22.31%
1 year
-31.76%
YTD
-27.34%
QTD
-26.01%

Financial performance

How have Sio Gene Therapies's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$42.2M
Net income
-$32.43M
Gross margin
N/A
Net margin
N/A
SIOX's net income has surged by 55% year-on-year and by 29% since the previous quarter
The operating income has increased by 39% YoY and by 8% from the previous quarter

Growth

What is Sio Gene Therapies's growth rate over time

Valuation

What is Sio Gene Therapies stock price valuation
P/E
N/A
P/B
0.96
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 79% YoY and by 43% QoQ
The equity has surged by 100% year-on-year and by 39% since the previous quarter
The price to book (P/B) is 86% lower than the 5-year quarterly average of 6.8 and 49% lower than the last 4 quarters average of 1.9

Efficiency

How efficient is Sio Gene Therapies business performance
SIOX's return on invested capital has surged by 88% year-on-year and by 53% since the previous quarter
The ROE has soared by 85% YoY and by 42% from the previous quarter
The company's return on assets has surged by 64% YoY and by 37% QoQ

Dividends

What is SIOX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SIOX.

Financial health

How did Sio Gene Therapies financials performed over time
Sio Gene Therapies's total liabilities has shrunk by 63% YoY but it has increased by 19% QoQ
The total assets has increased by 44% YoY and by 37% from the previous quarter
The debt is 99% smaller than the equity
The equity has surged by 100% year-on-year and by 39% since the previous quarter
SIOX's debt to equity has dropped by 96% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.